It has been suggested that rare adverse events identified in some studies only should not mask the overall cardiovascular and renal benefit of SGLT2 inhibitors, especially in people with type 2 diabetes at high cardiovascular risk.20 Here, SLC5A2 is linked to type 2 diabetes mellitus.